Long term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement

被引:0
作者
Marchetti, M [1 ]
Liberato, NL [1 ]
Ruperto, N [1 ]
Barosi, G [1 ]
机构
[1] Policlin San Matteo, IRCCS, Lab Informat Med, I-27100 Pavia, Italy
关键词
decision trees; decision support techniques; cost benefit analysis; heparin; low molecular weight therapeutic use; heparin economics; arthroplasty; replacement; hip adverse effects; thrombosis prevention and control;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective. Either low molecular weight heparin (LMWH) or unfractionated heparin (UH) may be used for the prophylaxis of post-operative venous thromboembolic disease (VTD) in elective hip replacement. This study was aimed at assessing the cost-effectiveness of LMWH over UH from the society perspective, which considers all the outcomes occurring in the lifelong time horizon. Design and Methods. A decision tree modeled the clinical outcomes and resources used in consequence of restricted (2 weeks) and extended (4 weeks) prophylaxis of VTD with LMWH or UH. Results. In the studied population, that of 67 year-old patients, restricted prophylaxis with LMWH saved 25 quality-adjusted days and $75 over UH. Extended prophylaxis provided a small additional benefit with additional cost savings. The incremental outcomes of the model proved independent of most parameters. Interpretation and Conclusions. We conclude that LMWH has considerable advantages over UH in the prophylaxis of VTD following elective hip replacement, and should be recommended in clinical practice. (C)1999, Ferrata Storti Foundation.
引用
收藏
页码:730 / 737
页数:8
相关论文
共 48 条
[1]   Prospective study of safety of lower extremity phlebography with nonionic contrast medium [J].
AbuRahma, AF ;
Powell, M ;
Robinson, PA .
AMERICAN JOURNAL OF SURGERY, 1996, 171 (02) :255-257
[2]   Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism [J].
Anderson, DR ;
OBrien, BJ .
PHARMACOECONOMICS, 1997, 12 (01) :17-29
[3]   EFFICACY AND COST OF LOW-MOLECULAR-WEIGHT HEPARIN COMPARED WITH STANDARD HEPARIN FOR THE PREVENTION OF DEEP-VEIN THROMBOSIS AFTER TOTAL HIP-ARTHROPLASTY [J].
ANDERSON, DR ;
OBRIEN, BJ ;
LEVINE, MN ;
ROBERTS, R ;
WELLS, PS ;
HIRSH, J .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (11) :1105-1112
[4]   CURRENT STATUS OF PULMONARY THROMBOEMBOLIC DISEASE - PATHO-PHYSIOLOGY, DIAGNOSIS, PREVENTION, AND TREATMENT [J].
BELL, WR ;
SIMON, TL .
AMERICAN HEART JOURNAL, 1982, 103 (02) :239-262
[5]   Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement [J].
Bergqvist, D ;
Benoni, G ;
Bjorgell, O ;
Fredin, H ;
Hedlundh, U ;
Nicolas, S ;
Nilsson, P ;
Nylander, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) :696-700
[6]   Cos of long-term complications of deep venous thrombosis of the lower extremities: An analysis of a defined patient population in Sweden [J].
Bergqvist, D ;
Jendteg, S ;
Johansen, L ;
Persson, U ;
Odegaard, K .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (06) :454-457
[7]   PREVENTION OF VENOUS THROMBOEMBOLISM [J].
CLAGETT, GP ;
ANDERSON, FA ;
HEIT, J ;
LEVINE, MN ;
WHEELER, HB .
CHEST, 1995, 108 (04) :S312-S334
[8]   LOW ACCURACY OF COLOR DOPPLER ULTRASOUND IN THE DETECTION OF PROXIMAL LEG VEIN-THROMBOSIS IN ASYMPTOMATIC HIGH-RISK PATIENTS [J].
DAVIDSON, BL ;
ELLIOTT, CG ;
LENSING, AWA .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (09) :735-738
[9]   Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement [J].
Detournay, B ;
Planes, A ;
Vochelle, N ;
Fagnani, F .
PHARMACOECONOMICS, 1998, 13 (01) :81-89
[10]   ECONOMIC-EVALUATION OF STANDARD HEPARIN AND ENOXAPARIN FOR PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS IN ELECTIVE HIP-SURGERY [J].
DRUMMOND, M ;
ARISTIDES, M ;
DAVIES, L ;
FORBES, C .
BRITISH JOURNAL OF SURGERY, 1994, 81 (12) :1742-1746